CG Invites Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
87
- Stock Symbol
-
083790
- Investments
-
12
- Share Price
-
$0.57
- (As of Friday Closing)
CG Invites General Information
Description
CrystalGenomics Invites Co Ltd Formerly CrystalGenomics Inc is one of the leading biopharmaceutical company in Korea. The company is mainly engaged in the research and development and new drug development. It develops innovative new drug development projects such as eradication antibiotics and molecular targeted anticancer drugs. It focuses on arthritic medicines and antibiotics which kill resistant bacteria. It also offers medicines for cancer, obesity, asthma, and diabetes.
Contact Information
Website
www.cginvites.comCorporate Office
- 38 Magokjungang 8
- Seoul, Gangseo
- South Korea
Corporate Office
- 38 Magokjungang 8
- Seoul, Gangseo
- South Korea
CG Invites Timeline
CG Invites Stock Performance
As of 13-Nov-2026, CG Invites’s stock price is $0.57. Its current market cap is $43.4M with 76.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.57 | $0.57 | $0.49 - $1.16 | $43.4M | 76.9M | 167K |
CG Invites Financials Summary
As of 30-Jun-2026, CG Invites has a trailing 12-month revenue of $20.7M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 76,468 | 110,318 | 125,488 | 151,523 |
| Revenue | 20,747 | 19,247 | 5,316 | 3,731 |
| EBITDA | (5,660) | (7,379) | (31,902) | (36,926) |
| Net Income | 296 | (2,474) | (37,777) | (37,419) |
| Total Assets | 142,613 | 155,630 | 176,830 | 188,655 |
| Total Debt | 29,448 | 32,264 | 36,292 | 24,834 |
CG Invites Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CG Invites Patents
CG Invites Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026112320-A1 | Use of multidose of ivaltinostat for treating cancer | Pending | 22-Nov-2024 | ||
| WO-2026038703-A1 | Biological age estimation device and method based on disease risk | Pending | 12-Aug-2024 | ||
| WO-2026038702-A1 | Comprehensive disease risk prediction device and method | Pending | 12-Aug-2024 | ||
| WO-2026038704-A1 | Comprehensive disease risk prediction device and method considering associated disease risk | Pending | 12-Aug-2024 | ||
| WO-2026038935-A1 | Periodic variable disease risk prediction device and method | Pending | 12-Aug-2024 |
CG Invites Signals
CG Invites Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CG Invites Investments & Acquisitions (12)
CG Invites’s most recent deal was a Joint Venture with VIDW. The deal was made on 17-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| VIDW | 17-Sep-2026 | Joint Venture | Enterprise Systems (Healthcare) | ||
| Guam Regional Medical City | 02-Jul-2024 | Merger/Acquisition | Clinics/Outpatient Services | ||
| Machaon Biotherapeutics | 15-Apr-2024 | Merger/Acquisition | Biotechnology | ||
| PanGen Biotech | 27-Mar-2024 | PIPE | Pharmaceuticals | ||
| PanGen Biotech | 22-Nov-2022 | PIPE | Pharmaceuticals |
CG Invites ESG
Risk Overview
Risk Rating
Updated August, 31, 2022
32.95 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
CG Invites Exits (3)
CG Invites’s most recent exit was on 07-Dec-2015 from HuonsLifeSciences. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| HuonsLifeSciences | 07-Dec-2015 | Completed |
|
||
| Palkion | 17-Aug-2009 | Completed |
|
||
| Palkion | 01-Mar-2008 | Early Stage VC | Completed |
|
CG Invites Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Invites Ventures | Seoul, South Korea | 2019 | |
| Guam Regional Medical City | Dededo, GU | 2015 | |
| BexPharm Healthcare | Seoul, South Korea | 1998 | |
| Hwail Pharmaceutical | Pyeongtaek, South Korea | 1974 |
CG Invites FAQs
-
When was CG Invites founded?
CG Invites was founded in 2000.
-
Where is CG Invites headquartered?
CG Invites is headquartered in Seoul, South Korea.
-
What is the size of CG Invites?
CG Invites has 87 total employees.
-
What industry is CG Invites in?
CG Invites’s primary industry is Drug Discovery.
-
Is CG Invites a private or public company?
CG Invites is a Public company.
-
What is CG Invites’s stock symbol?
The ticker symbol for CG Invites is 083790.
-
What is the current stock price of CG Invites?
As of 13-Nov-2026 the stock price of CG Invites is $0.57.
-
What is the current market cap of CG Invites?
The current market capitalization of CG Invites is $43.4M.
-
What is CG Invites’s current revenue?
The trailing twelve month revenue for CG Invites is $20.7M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process